A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 5, 2013, Pages 697-705

  Domont, Julien ^a   Massard, Christophe ^a   Patrikidou, Anna ^a   Bossi, Alberto ^a   de Crevoisier, Renaud ^a   Rose, Mathieu ^a   Wibault, Pierre ^a   Fizazi, Karim ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Radiotherapy; Seminoma; Stage II

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DISEASE SEVERITY; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION FIELD; RECURRENCE FREE SURVIVAL; SEMINOMA;

ADULT; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; EAR DISEASES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; NERVOUS SYSTEM DISEASES; RISK FACTORS; SEMINOMA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879463263     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.04.004     Document Type: Article

References (43)

1. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Jemal A., Siegel R., Xu J., et al. Cancer Statistics 2010. CA Cancer J Clin 2010, 60:277-300.
3. Classen J., Schmidberger H., Meisner C., et al. radiotherapy for stage IIA/B testicular seminoma: Final report a prospective multicenter clinical trial. J Clin Oncol 2003, 21:1101-1106.
4. Ball C., Barrett A., Peckham M.J., et al. The management of metastatic seminoma testis. Cancer 1982, 50:2285-2294.
5. Warde P., Gospodarowicz M., Panzarella T., et al. Management of stage II seminoma. J Clin Oncol 1998, 16:290-294.
6. Schmoll H.J., Souchon R., Krege S., et al. European consensus on diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004, 15:1377-1399.
7. Zagars G.K., Ballo M.T., Lee A.K., et al. Mortality after cure of testicular seminoma. J Clin Oncol 2004, 22:640-647.
8. Travis L.B., Fossa S.D., Schonfeld S.J., et al. Second cancers among 40,576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 2005, 97:1354-1365.
9. Huddart R.A., Norman A.R., Shahidi M., et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003, 21:585-588.
10. Fizazi K., Chen I., Logothetis C.J. Germ cell tumor survivors: The price for cure. Ann Oncol 2002, 13:187-189.
11. Horwich A. Radiotherapy in stage I seminoma of the testis. J Clin Oncol 2004, 22:585-588.
12. Lederman G.S., Sheldon T.A., Chaffey J.T., et al. Cardiac disease after mediastinal irradiation for seminoma. Cancer 1987, 60:772-776.
13. Souchon R., Krege S., Schmoll H.J., et al. Interdisciplinary consensus on diagnosis and therapy of testicular tumors: Results of an update conference based on evidence-based medicine. German Testicular Cancer study Group (GTCSG). Strahlenther Onkol 2000, 176:388-405.
14. Schmidberger H., Bamberg M., Meisner C., et al. Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: A prospective multicenter study. Int J Radiat Oncol Biol Phys 1997, 39:321-326.
15. Weissbach L., Bussar-Maatz R., Löhrs U., et al. Prognostic factors in seminomas with special respect to HCG: Results of a prospective multicenter study. Eur Urol 1999, 36:601-608.
16. Zagars G.K., Pollack A. Radiotherapy for stage II testicular seminoma. Int J Radiat Oncol Biol Phys 2001, 51:643-649.
17. Patterson H., Norman A.R., Mitra S.S., et al. Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: Comparison with radiotherapy treatment alone. Radiother Oncol 2001, 59:5-11.
18. Krege S., Boergermann C., Baschek R., et al. Single agent carboplatin for CS IIA/B testicular seminoma: A phase II study of the German Testicular Cancer Study Group (GTCSG). Ann Oncol 2006, 17:276-280.
19. Arranz Arija J.A., Garci'a del Muro X., Guma J., et al. E400P in advanced seminoma of good prognosis according to the International Germ Cell Cancer Collaborative Group (IGCCCG) classification: The Spanish Germ Cell Cancer Group experience. Ann Oncol 2001, 12:487-491.
20. Bamberg M., Schimdberger H., Meisner C., et al. Radiotherapy for stages I and IIA/B testicular seminoma. Int J Cancer 1999, 83:823-827.
21. Chung P.W., Gsodarowicz M.K., Panzarella T., et al. Stage II testicular seminoma: Patterns of recurrence and outcome of treatment. Urol Oncol 2005, 23:140-141.
22. Porcaro A.B., Antoniolli S.Z., Maffei N., et al. Management of testicular seminoma advanced disease. Report of 14 cases and review of the literature. Arch Ital Urol Androl 2002, 74:81-85.
23. Garcia-Serra A.M., Zlotecki R.A., Morris C.G., et al. Long-term results of radiotherapy for early-stage testicular seminoma. Am J Clin Oncol 2005, 28:119-124.
24. Garcia-del-Muro X., Maroto P., Gumà J., et al. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular semininoma: A Spanish Germ Cell Cancer Group study. J Clin Oncol 2008, 26:5416-5421.
25. Detti B., Livi L., Scoccianti S., et al. Management of stage II testicular seminoma over a period of 40 years. Urol Oncol 2009, 27:534-538.
26. Mountzios G., Bamias A., Koutsoukou V., et al. Cisplatin-based chemotherapy for advanced seminoma: Report of 52 cases treated at two institutions. J Cancer Res Clin Oncol 2009, 135:1495-1500.
27. Gilbert D.C., Vanas N.J., Beesley S., et al. Treating IIA/B seminoma with combination carboplatin and radiotherapy. J Clin Oncol 2009, 27:2101-2102.
28. de Wit R., Roberts J.T., Wilkinson P.M., et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin in good-prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001, 19:1629-1640.
29. de Wit R., Stoter G., Kaye S.B., et al. Importance of bleomycin in favorable good-prognosis testicular non-seminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 1997, 15:1831-1843.
30. Lohrer P.J., Johnson D., Elson P., et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial. J Clin Oncol 1995, 13:470-476.
31. Culine S., Kerbrat P., Kramar A., et al. Refining the optimal chemotherapy regimen for good-risk metastatic non-seminomatous germ-cell tumors: A randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 2007, 18:917-924.
32. Fizazi K., Culine S., Droz J.P., et al. Initial management of primary mediastinal seminoma: Radiotherapy or cisplatin-based chemotherapy?. Eur J Cancer 1998, 34:347-352.
33. Mencel P.J., Motzer R.J., Mazumdar M., et al. Advanced seminoma: Treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 1994, 12:120-126.
34. Gholam D., Fizazi K., Terrier-Lacombe M.J., et al. Advanced seminoma: Treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: A single-institution experience in 145 patients. Cancer 2003, 98:745-752.
35. Bokemeyer C., Kollmannsberger C., Stenning S., et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: A pooled analysis of two randomized trials. Br J Cancer 2004, 91:683-687.
36. Krege S., Beyer J., Souchon R., et al. European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG). Eur Urol 2008, 53:478-496.
37. Fizazi K., Tjulandin S., Salvioni R., et al. Viable malignant cells after primary chemotherapy for disseminated non-seminomatous germ cell tumors: Prognostic factors and role of postsurgery chemotherapy: Results from an international study group. J Clin Oncol 2001, 19:2647-2657.
38. Fizazi K., Oldenburg J., Dunant A., et al. Assessing prognosis and optimizing treatment in patients with post-chemotherapy viable non-seminomatous germ-cell tumors (NSGCT): Results of the sCR2 International study. Ann Oncol 2008, 19:259-264.
39. Duchesne G.M., Stenning S.P., Aass N., et al. Radiotherapy after chemotherapy for metastatic seminoma: A diminishing role. Eur J Cancer 1997, 33:829-835.
40. Puc H.S., Heelan R., Mazumdar M., et al. Management of residual mass in advanced seminoma: Results and recommendations from the Memorial Sloan Kettering Cancer Center. J Clin Oncol 1996, 14:454-460.
41. Flechon A., Bompas E., Biron P., et al. Management of post-chemotherapy residual masses in advanced seminoma. J Urol 2002, 168:1975-1979.
42. Culine S., Droz J.P. Optimal management of residual mass after chemotherapy in advanced seminoma: There is time for everything. J Clin Oncol 1996, 14:2884-2885.
43. de Santis M., Becherer A., Bokemeyer C., et al. 18Fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in post-chemotherapy seminoma: An update of the prospective multicentric SEMPET trial. J Clin Oncol 2004, 22:1034-1039.